← ANALYST RATINGS · TIPRANKS
Teleflex (TFX): analyst forecast and price target
Analyst consensus
Moderate Buy5 Buy3 Hold0 Sell
Ratings of 8 analysts in the last 3 months12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $156, the highest $170, the lowest $140. The average is +19.5% from the last price of $130.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Travis Steed★★★★★★★★★★#3596 · hits 53% · avg +3.0% | Bank of America Securities | $158 | Buy | +21.1% | Reiterated | 16.10.26on TipRanks 07:25 | +2.8% | ↗ |
| Richard Newitter★★★★★★★★★★#1772 · hits 48% · avg +6.6% | Truist Financial | $150 → $142−5.3% | Hold | +8.9% | Reiterated | 14.10.26on TipRanks 08:35 | +0.2%next day +3.7% | ↗ |
| Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% | Mizuho Securities | $145 → $140−3.4% | Hold | +7.3% | Assigned | 13.10.26on TipRanks 07:35 | −1.0%next day +0.2% | ↗ |
| Name not given | — | $155 | Buy | +18.8% | Reiterated | 01.10.26on TipRanks Oct 2 21:45 | +0.7%next day −2.3% · 5 days −2.8% | ↗ |
| AI xAi Medical - Instruments and SuppliesxAI Grok-3 | TipRanks - xAI | $128 | Hold | −1.9% | Reiterated | 29.09.26on TipRanks Sep 28 23:06 | — | |
| AI DeepSeek Medical - Instruments and SuppliesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $125 | Hold | −4.2% | Reiterated | 29.09.26on TipRanks Sep 28 23:06 | — | |
| AI OpenAI Medical - Instruments and SuppliesOpenAI 5.2 | TipRanks - OpenAI | $127 | Hold | −2.6% | Reiterated | 29.09.26on TipRanks Sep 28 23:06 | — | |
| AI Anthropic Medical - Instruments and SuppliesAnthropic Opus-4.5 | TipRanks - Anthropic | $125 | Hold | −4.2% | Reiterated | 29.09.26on TipRanks Sep 28 23:06 | — | |
| AI Google Medical - Instruments and SuppliesGemini 3-pro | TipRanks - Google | $129 | Hold | −1.1% | Reiterated | 29.09.26on TipRanks Sep 28 23:06 | — | |
| AI PerPlexity Medical - Instruments and SuppliesPerPlexity SonarPro | TipRanks - PerPlexity | $126 | Hold | −3.4% | Reiterated | 29.09.26on TipRanks Sep 28 23:06 | — | |
| Jason Bednar★★★★★★★★★★#11450 · hits 46% · avg −2.5% | Piper Sandler | $169 | Buy | +29.6% | Reiterated | 18.09.26on TipRanks 07:45 | −1.0%next day −1.3% · 5 days −3.2% | ↗ |
| Michael Matson★★★★★★★★★★#1853 · hits 50% · avg +6.0% | Needham | $159 → $170+6.9% | Buy | +30.3% | Assigned | 25.08.26on TipRanks 06:16 | +1.0%next day −1.0% · 5 days +0.8% | ↗ |
| Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% | UBS | $145 → $158+9.0% | Hold | +21.1% | Reiterated | 11.08.26on TipRanks 08:55 | +0.7%next day +1.8% · 5 days −0.6% | ↗ |
| Ravi Misra★★★★★★★★★★#11202 · hits 35% · avg −10.7% | Truist Financial | $143 → $150+4.9% | Hold | +15.0% | Reiterated | 10.08.26on TipRanks 07:55 | −1.4%next day +0.7% · 5 days +0.3% | ↗ |
| Jayson Bedford★★★★★★★★★★#819 · hits 60% · avg +8.6% | Raymond James | $150 → $155+3.3% | Buy | +18.8% | Reiterated | 07.08.26on TipRanks 09:55 | −3.4%next day −1.4% · 5 days +1.5% | ↗ |
| Vik Chopra★★★★★★★★★★#6076 · hits 45% · avg +1.9% | BMO Capital | $159 | Buy | +21.9% | Initiated | 09.07.26on TipRanks 06:15 | +2.0%next day +0.8% · 5 days +1.0% | ↗ |
| Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% | Wells Fargo | $130 → $138+6.2% | Hold | +5.8% | Reiterated | 08.05.26on TipRanks 07:30 | +0.2%next day −2.7% · 5 days −2.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Teleflex
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 13.10.26: target $157 at a price of $126 (+24.8%); now: $156 at $130 (+19.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 5 | 4 | 7 | 9 | 10 | 9 |
| Hold | 9 | 8 | 5 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 22.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.90 (from $1.76 to $2.04). Last quarter: $1.76.
Sales
Next quarter’s sales estimate — $566M (from $564M to $569M). Last quarter: $570M.
Best top-analyst consensus in the sector · Healthcare
About Teleflex
- CEO: Jason Weidman
- Employees: 15,500
- 550 East Swedesford Road, Wayne, PA, 19087-1603, US
- www.teleflex.com
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spiromet
Data from the stock’s TipRanks forecast page, read 43 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗